Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference
March 01, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 14, 2022 16:01 ET
|
Vera Therapeutics
BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
February 10, 2022 08:46 ET
|
Vera Therapeutics
BRISBANE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”) (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
February 07, 2022 17:24 ET
|
Vera Therapeutics
BRISBANE, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis
January 18, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
December 17, 2021 07:30 ET
|
Vera Therapeutics
Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of...
Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors
December 14, 2021 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021
November 10, 2021 16:15 ET
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 07:15 ET
|
Vera Therapeutics
Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a...